GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (FRA:NV4) » Definitions » ROE % Adjusted to Book Value

Cellectar Biosciences (FRA:NV4) ROE % Adjusted to Book Value : -49.24% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cellectar Biosciences ROE % Adjusted to Book Value?

Cellectar Biosciences's ROE % for the quarter that ended in Mar. 2024 was -695.75%. Cellectar Biosciences's PB Ratio for the quarter that ended in Mar. 2024 was 14.13. Cellectar Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -49.24%.


Cellectar Biosciences ROE % Adjusted to Book Value Historical Data

The historical data trend for Cellectar Biosciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences ROE % Adjusted to Book Value Chart

Cellectar Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50.82 -17.15 -44.56 -116.08 -

Cellectar Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -136.24 - - - -49.24

Competitive Comparison of Cellectar Biosciences's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Cellectar Biosciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectar Biosciences's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's ROE % Adjusted to Book Value falls into.



Cellectar Biosciences ROE % Adjusted to Book Value Calculation

Cellectar Biosciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-519.97% / N/A
=N/A

Cellectar Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-695.75% / 14.13
=-49.24%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellectar Biosciences ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectar Biosciences (FRA:NV4) Business Description

Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Cellectar Biosciences (FRA:NV4) Headlines

No Headlines